There is no doubt that the advanced therapies sector is growing at an exponential rate. According to a recently published 2021 Report by ARM (Alliance for Regenerative Medicine), the sector has raised $14.1B in financing in the first half of 2021 which is already 71% of what was raised in all of 2020. In addition, there are over 2,600 advanced therapy clinical trials being conducted with 264 of those trials being Phase 3 trials and another 1,500 being Phase 2 trials.

With a maturing pipeline, more and more products are approaching the point of development where pricing decisions and evidence will be used to support payer and HTA engagement. Our panel of industry experts will discuss some of these considerations when preparing for the launch of an advanced therapy.

Important evidence needed to support pricing decisions
How evidence differs between cell and gene therapies and by market assessment archetype
How organizations are thinking about advocacy and integrating the voice of the patient to guide evidence development and payer engagement
Insights into the evolution of price, evidence generation, reimbursement decisions, and contracting strategies as the cell and gene therapy industry continues to grow

Click here for additional information and registration details.

Related Content

Evidence Matters 2022

Evidence Matters 2022

Evidence Matters is a virtual one-day summit that brings the literature review community together from different industries to learn, engage, and solve ever-pressing evidence-based research challenges.